RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
RNAimmune, Inc., a biopharmaceutical company specializing in discovery and development of mRNA-based therapeutics and vaccines, announced today that is has...
